Publications by authors named "C C OPRESCU"
Logistics for achieving delivery: A secondary analysis of the home induction randomised controlled trial.
Eur J Obstet Gynecol Reprod Biol
February 2025
Article Synopsis
- The study analyzed the effectiveness and logistics of vaginal delivery following outpatient induction of labor using different cervical ripening methods.
- Results showed that most women (94%) delivered within 72 hours of induction, with varying rates of readmission and need for additional treatments between the different methods.
- The findings suggest that specific protocols for outpatient induction can lead to high vaginal delivery rates and inform future practices in labor induction services.
Although laparoscopy has some limitations related to tumor size or location along the colon, it has been demonstrated that the oncological results are just as good as for open surgery. One can also add to the benefits faster recovery and start of chemotherapy, with lower rates of complications. Our study aimed to compare open surgery to laparoscopy for non-complicated colon tumors operated in an average case-load center and appreciate its feasibility with regards to the T stage, lymph node yield and conversions.
View Article and Find Full Text PDFBackground: The increased demand for induction of labour (IOL) at 39 weeks' gestation in normal-risk nulliparous patients creates significant logistical challenges for busy maternity units. A potential innovation is commencing induction by means of outpatient cervical ripening, using either a vaginal prostaglandin preparation (Propess) or an osmotic cervical dilator (Dilapan-S).
Methods: A Phase III, open label, single centre non-inferiority trial (EudraCT number 2019-004697-25) randomised healthy nulliparous women who chose elective IOL at 39 weeks to one of three methods of initial cervical ripening, specifically 12 h of Dilapan-S(D12), 24 h of Dilapan-S(D24), or 24 h of Propess(P24) between November 2020 and July 2023.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) are now a key first-line treatment for many cancers and are increasingly recommended as adjuvant therapy, but their use is also associated with immune-mediated adverse reactions.
- Common adverse effects include immune-mediated diarrhea, colitis, hepatitis, and pancreatic damage, which are becoming more frequent as ICIs are more widely used.
- This review synthesizes findings from 30 relevant studies to enhance understanding among gastroenterologists about diagnosing and treating these toxicities, aiming to raise awareness and improve treatment guidelines.